![Pharmaceuticals | Free Full-Text | Pharmacokinetics and Pharmacogenetics of Cyclophosphamide in a Neonate and Infant Childhood Cancer Patient Population Pharmaceuticals | Free Full-Text | Pharmacokinetics and Pharmacogenetics of Cyclophosphamide in a Neonate and Infant Childhood Cancer Patient Population](https://www.mdpi.com/pharmaceuticals/pharmaceuticals-14-00272/article_deploy/html/images/pharmaceuticals-14-00272-g001.png)
Pharmaceuticals | Free Full-Text | Pharmacokinetics and Pharmacogenetics of Cyclophosphamide in a Neonate and Infant Childhood Cancer Patient Population
![Comparison of short interval and low dose (SILD) with high dose of cyclophosphamide in the susceptibility to infection in SLE: a multicentrereal-world study | Lupus Science & Medicine Comparison of short interval and low dose (SILD) with high dose of cyclophosphamide in the susceptibility to infection in SLE: a multicentrereal-world study | Lupus Science & Medicine](https://lupus.bmj.com/content/lupusscimed/9/1/e000779/F1.large.jpg)
Comparison of short interval and low dose (SILD) with high dose of cyclophosphamide in the susceptibility to infection in SLE: a multicentrereal-world study | Lupus Science & Medicine
![Comparison of Dose Adjustment Strategies for Obesity in High-dose Cyclophosphamide Among Adult Hematopoietic Cell Transplantation Recipients: Pharmacokinetic Analysis - Transplantation and Cellular Therapy, Official Publication of the American Society ... Comparison of Dose Adjustment Strategies for Obesity in High-dose Cyclophosphamide Among Adult Hematopoietic Cell Transplantation Recipients: Pharmacokinetic Analysis - Transplantation and Cellular Therapy, Official Publication of the American Society ...](https://www.astctjournal.org/cms/asset/9128c19c-393e-4e3e-90aa-ce3b3f824fc5/ga1.jpg)
Comparison of Dose Adjustment Strategies for Obesity in High-dose Cyclophosphamide Among Adult Hematopoietic Cell Transplantation Recipients: Pharmacokinetic Analysis - Transplantation and Cellular Therapy, Official Publication of the American Society ...
![Frontiers | High-Dose Cyclophosphamide Administration Orchestrates Phenotypic and Functional Alterations of Immature Dendritic Cells and Regulates Th Cell Polarization Frontiers | High-Dose Cyclophosphamide Administration Orchestrates Phenotypic and Functional Alterations of Immature Dendritic Cells and Regulates Th Cell Polarization](https://www.frontiersin.org/files/Articles/548602/fphar-11-00775-HTML/image_m/fphar-11-00775-g001.jpg)
Frontiers | High-Dose Cyclophosphamide Administration Orchestrates Phenotypic and Functional Alterations of Immature Dendritic Cells and Regulates Th Cell Polarization
![Pharmaceuticals | Free Full-Text | Pharmacokinetics and Pharmacogenetics of Cyclophosphamide in a Neonate and Infant Childhood Cancer Patient Population Pharmaceuticals | Free Full-Text | Pharmacokinetics and Pharmacogenetics of Cyclophosphamide in a Neonate and Infant Childhood Cancer Patient Population](https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-14-00272/article_deploy/html/images/pharmaceuticals-14-00272-g003.png?1616232849)
Pharmaceuticals | Free Full-Text | Pharmacokinetics and Pharmacogenetics of Cyclophosphamide in a Neonate and Infant Childhood Cancer Patient Population
![Immunological Effects of Low-dose Cyclophosphamide in Cancer Patients Treated With Oncolytic Adenovirus: Molecular Therapy Immunological Effects of Low-dose Cyclophosphamide in Cancer Patients Treated With Oncolytic Adenovirus: Molecular Therapy](https://www.cell.com/cms/attachment/cd22f0c8-1524-4c03-b666-7a80d91c712d/gr1_lrg.jpg)
Immunological Effects of Low-dose Cyclophosphamide in Cancer Patients Treated With Oncolytic Adenovirus: Molecular Therapy
![The effect of granulocyte-colony stimulating factor, decitabine, and busulfan–cyclophosphamide versus busulfan–cyclophosphamide conditioning on relapse in patients with myelodysplastic syndrome or secondary acute myeloid leukaemia evolving from ... The effect of granulocyte-colony stimulating factor, decitabine, and busulfan–cyclophosphamide versus busulfan–cyclophosphamide conditioning on relapse in patients with myelodysplastic syndrome or secondary acute myeloid leukaemia evolving from ...](https://www.thelancet.com/cms/attachment/36095ed8-7b85-4a20-8bc4-3ac4fa70ecad/gr1_lrg.jpg)
The effect of granulocyte-colony stimulating factor, decitabine, and busulfan–cyclophosphamide versus busulfan–cyclophosphamide conditioning on relapse in patients with myelodysplastic syndrome or secondary acute myeloid leukaemia evolving from ...
![These highlights do not include all the information needed to use CYCLOPHOSPHAMIDE CAPSULES safely and effectively. See full prescribing information for CYCLOPHOSPHAMIDE CAPSULES CYCLOPHOSPHAMIDE capsules, for oral use Initial U.S. Approval:1959 These highlights do not include all the information needed to use CYCLOPHOSPHAMIDE CAPSULES safely and effectively. See full prescribing information for CYCLOPHOSPHAMIDE CAPSULES CYCLOPHOSPHAMIDE capsules, for oral use Initial U.S. Approval:1959](https://dailymed.nlm.nih.gov/dailymed/image.cfm?name=f57dbebf-f145-4e3c-bfef-b7907f6e01eb-02.jpg&id=554031)
These highlights do not include all the information needed to use CYCLOPHOSPHAMIDE CAPSULES safely and effectively. See full prescribing information for CYCLOPHOSPHAMIDE CAPSULES CYCLOPHOSPHAMIDE capsules, for oral use Initial U.S. Approval:1959
![Formulation Options for Cyclophosphamide : February 2022 : Oncology Safety - Pharmacy Purchasing & Products Magazine Formulation Options for Cyclophosphamide : February 2022 : Oncology Safety - Pharmacy Purchasing & Products Magazine](https://www.pppmag.com/files/article-images/ppp_2202_onc_patientsafety_figure.jpg)
Formulation Options for Cyclophosphamide : February 2022 : Oncology Safety - Pharmacy Purchasing & Products Magazine
![Pazopanib and Oral Cyclophosphamide in Women With Platinum-Resistant or -Refractory Epithelial Ovarian Cancer | JCO Global Oncology Pazopanib and Oral Cyclophosphamide in Women With Platinum-Resistant or -Refractory Epithelial Ovarian Cancer | JCO Global Oncology](https://ascopubs.org/na101/home/literatum/publisher/asco/journals/content/go/2020/go.2020.6/jgo.19.00331/20200328/images/large/jgo.19.00331t3.jpeg)
Pazopanib and Oral Cyclophosphamide in Women With Platinum-Resistant or -Refractory Epithelial Ovarian Cancer | JCO Global Oncology
![Dosing of mesna to avoid urothelial toxicity from cyclophosphamide infusion - Journal of Prescribing Practice Dosing of mesna to avoid urothelial toxicity from cyclophosphamide infusion - Journal of Prescribing Practice](https://www.prescribingpractice.com/media/bp5fx5du/calculation_16_1000x667.jpg)